Danaher Stock: Analyst Predictions and Market Performance

Danaher Corporation, a science and technology company, has declined by 22.2% over the past 52 weeks. Its shares have also underperformed the sector-specific Robo Global Healthcare Technology and Innovation ETF. Despite a weak price action, Danaher's recent quarterly financials came in better than expected, sparking a 4.2% surge in its share. Wall Street analysts expect a modest growth in Danaher's bottom line for fiscal year 2025, forecasting a 3.9% YOY growth in EPS to $7.77 on a diluted basis. The consensus rating among analysts covering Danaher's stock is a "Strong Buy."

Danaher Corporation (DHR), a science and technology company based in Washington, D.C., has seen its stock decline by 22.2% over the past 52 weeks. This performance has lagged behind the broader S&P 500 Index, which has gained 19% during the same period. Additionally, Danaher's shares have underperformed the sector-specific Robo Global Healthcare Technology and Innovation ETF (HTEC), which has gained 5.2% over the past 52 weeks and 4.7% year-to-date (YTD) [1].

Despite the weak price action, Danaher's recent quarterly financials exceeded expectations, sparking a 4.2% surge in its share price on July 23. For the second quarter of fiscal 2025, the company reported sales of $5.94 billion, an increase of 3.4% year-over-year (YOY), which was better than the $5.84 billion expected by Wall Street analysts. This growth was driven by the Danaher Business System and gains in its bioprocessing business [1].

For the fiscal year 2025, ending in December 2025, Wall Street analysts expect a modest growth in Danaher's bottom line, forecasting a 3.9% YOY growth in its EPS to $7.77 on a diluted basis. The company has a mixed history of surpassing consensus estimates, topping them in three of the trailing four quarters and missing them on one occasion [1].

Among the 23 analysts covering Danaher's stock, the consensus is a "Strong Buy," based on 19 "Strong Buy" ratings, one "Moderate Buy" rating, and three "Holds." This configuration appears slightly more bullish than two months ago when the stock had 18 "Strong Buy" ratings [1].

Highlighting confidence in the company’s prospects, Guggenheim analyst Subbu Nambi maintained a "Buy" rating on Danaher's stock in late July and reiterated the $250 price target. Additionally, Baird analyst Catherine Schulte reaffirmed the firm’s "Outperform" rating, while raising the price target on the stock from $226 to $229 [1].

Danaher's mean price target of $243.33 indicates a premium of 16.3% from the current market prices. The Street-high price target of $310 implies a potential upside of 48.2% [1].

References:
[1] https://www.archercoopgrain.com/news/story/34154978/are-wall-street-analysts-predicting-danaher-stock-will-climb-or-sink
[2] https://www.barchart.com/story/news/34154977/are-wall-street-analysts-predicting-danaher-stock-will-climb-or-sink